tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AbbVie Shines in Earnings Call with Strong Growth
Company AnnouncementsAbbVie Shines in Earnings Call with Strong Growth
8h ago
ABBV
AbbVie price target raised to $227 from $216 at Guggenheim
PremiumThe Fly
AbbVie price target raised to $227 from $216 at Guggenheim
20h ago
ABBV
AbbVie price target raised to $207 from $205 at Evercore ISI
PremiumThe Fly
AbbVie price target raised to $207 from $205 at Evercore ISI
20h ago
ABBV
AbbVie price target raised to $236 from $227 at Raymond James
PremiumThe Fly
AbbVie price target raised to $236 from $227 at Raymond James
20h ago
ABBV
AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
PremiumRatings
AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
22h ago
ABBV
AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
PremiumRatingsAbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
1d ago
ABBV
AbbVie Reports Strong Q2 2025 Financial Results
Premium
Company Announcements
AbbVie Reports Strong Q2 2025 Financial Results
1d ago
ABBV
Trump posts letters calling on drug company CEOs to lower prices
Premium
The Fly
Trump posts letters calling on drug company CEOs to lower prices
2d ago
AZN
BMY
AbbVie says ‘fairly insulated’ from any tariff impacts this year
PremiumThe Fly
AbbVie says ‘fairly insulated’ from any tariff impacts this year
2d ago
ABBV
AbbVie sees Q3 adjusted EPS $3.24-$3.28, consensus $3.24
PremiumThe Fly
AbbVie sees Q3 adjusted EPS $3.24-$3.28, consensus $3.24
2d ago
ABBV
AbbVie sees FY25 adjusted gross margin 84% of sales
PremiumThe Fly
AbbVie sees FY25 adjusted gross margin 84% of sales
2d ago
ABBV
AbbVie says well positioned to deliver in FY25 and beyond
PremiumThe Fly
AbbVie says well positioned to deliver in FY25 and beyond
2d ago
ABBV
Morning Movers: Roblox skyrockets following second quarter results
PremiumThe FlyMorning Movers: Roblox skyrockets following second quarter results
2d ago
K
CI
AbbVie raises FY25 revenue view to $60.5B from ~$59.7B, consensus $60.01B
Premium
The Fly
AbbVie raises FY25 revenue view to $60.5B from ~$59.7B, consensus $60.01B
2d ago
ABBV
AbbVie raises FY25 adjusted EPS view to $11.88-$12.08 from $11.67-$11.87
Premium
The Fly
AbbVie raises FY25 adjusted EPS view to $11.88-$12.08 from $11.67-$11.87
2d ago
ABBV
AbbVie reports Q2 adjusted EPS $2.97, consensus $2.91
PremiumThe Fly
AbbVie reports Q2 adjusted EPS $2.97, consensus $2.91
2d ago
ABBV
AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
PremiumThe Fly
AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
2d ago
ABBV
AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
PremiumThe Fly
AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
2d ago
ABBV
Notable companies reporting before tomorrow’s open
PremiumThe Fly
Notable companies reporting before tomorrow’s open
3d ago
K
CI
AbbVie reports results from Phase 3 UP-AA clinical program
PremiumThe FlyAbbVie reports results from Phase 3 UP-AA clinical program
3d ago
ABBV
AbbVie submits sNDA to the FDA for oral combination in lymphocytic leukemia
Premium
The Fly
AbbVie submits sNDA to the FDA for oral combination in lymphocytic leukemia
4d ago
ABBV
AbbVie’s telisotuzumab adizutecan receives FDA orphan designation
Premium
The Fly
AbbVie’s telisotuzumab adizutecan receives FDA orphan designation
5d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >